Related Experiment Video

Updated: Oct 4, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Protein kinase C isozymes, novel phorbol ester receptors and cancer chemotherapy

O P Barry1, M G Kazanietz

  • 1Cork Cancer Research Center and Department of Medicine, Clinical Science Building, Cork University Hospital, Wilton Road, Cork, Ireland. goggieie@yahoo.com

Current Pharmaceutical Design
|September 20, 2001
PubMed

Insights

Researchers are developing targeted activators and inhibitors for Protein Kinase C (PKC) isozymes, crucial in cell signaling, for novel cancer therapies. These new agents show promise and are advancing through clinical trials for better cancer treatment.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Protein Kinase C (PKC) isozymes regulate cell proliferation and death.
  • PKC signaling pathways are critical targets for cancer therapy.
  • Understanding PKC isozyme roles and receptors has significantly advanced.

Purpose of the Study:

  • To review the development of selective activators and inhibitors for individual PKC isozymes.
  • To highlight the therapeutic potential of these compounds as anticancer agents.
  • To discuss the future implications for cancer treatment and understanding.

Main Methods:

  • Review of recent scientific literature on PKC isozymes and phorbol ester receptors.
  • Analysis of newly developed PKC activators and inhibitors.
  • Examination of compounds currently in clinical trials.

Main Results:

  • A large number of selective PKC activators and inhibitors have been developed.
  • Several compounds are demonstrating potential as anticancer agents.
  • A significant portion of these agents have progressed to Phase II clinical testing.

Conclusions:

  • Targeted modulation of PKC pathways offers a promising strategy for cancer therapy.
  • New generations of chemotherapeutic agents are being designed based on PKC research.
  • Advancements in understanding PKC signaling will lead to improved cancer treatments.

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Amplifying Signals via Second Messengers01:15

Amplifying Signals via Second Messengers

Many receptor binding ligands are hydrophilic; they do not cross the cell membrane but bind to cell-surface receptors. Thus, their message must be relayed by second messengers present in the cell cytoplasm. There are several second messenger pathways, each with its own way of relaying information. For example, the G protein-coupled receptors can activate both phosphoinositol and cyclic AMP (cAMP) second messenger pathways. The phosphoinositol pathway is active when the receptor induces...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...